Podcasts about Pharma

Send us a textJesse Mendelsohn and Michael Grosberg from Model N discuss why U.S. pricing complexity is spreading globally, the collapse of the PBM rebate model, what's really driving the pharmaceutical manufacturing boom, and why direct-to-consumer discount programs won't solve America's drug access problem.00:00 Introduction to Life Science Success Podcast00:34 Pressing Issues in Pharmaceutical Manufacturing00:51 Introducing the Experts from Model N03:08 Understanding International Reference Pricing04:14 Impact of US Pricing on Global Drug Launches09:26 Challenges with Pharmacy Benefit Managers16:29 Domestic Manufacturing Boom in Pharmaceuticals23:08 AI in Drug Discovery and Personalized Medicine29:03 Access and Policy Discussion30:01 Direct to Consumer Pricing31:32 TrumpRx Overview33:11 Compliance Challenges38:30 Pharmaceutical Revenue Management41:38 AI in Life Sciences48:35 Future of Life Sciences50:45 Concerns and Challenges53:52 Excitement in Current Work55:54 Conclusion and Final Thoughts

Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Click On Picture To See Larger PictureTrump started to put all the pieces together starting back in 2017. He was setting the stage to remove NAFTA but he was not able to because congress put roadblocks into the legislation, so he transitioned it into the USMCA and now he has trapped Canada in it. Trade deals are power of the US, the US has the leverage and the [CB] knows it.  The [DS] along with Biden, Obama and Clinton are pushing the insurgency in this country. Walz believes he has the upper hand making a deal with Trump but this is going to backfire on him and Frey. The people in MN are already upset. The D’s believe they can shutdown the government and use the DHS funding to do it. But the OBBB is funding ICE so this is going to fail. Trump has the leverage and he weakening the [DS] every step of the way. The root cause is being exposed to the country.   Economy Big Picture: President Trump and Trade Using the Art of the Self-Fulfilling Prophecy Canada and the EU take trade and economic positions seemingly against U.S. interests. Simultaneously Mexico modifies all their trade positions to come into alignment with the USA. Yesterday, Mexican President Claudia Sheinbaum announced Mexico will no longer ship oil to Cuba.   When President Trump was asked about Prime Minister Mark Carney creating a new trade agreement with China, President Trump responded that he didn't care – it was irrelevant to him.  Yet, simultaneously inside the USMCA President Trump has the power to veto any trade agreement between Mexico or Canada and a non-member nation. So, why didn't President Trump care?  Easy, because in President Trump's mind there's not going to be a USMCA; so, he really doesn't care if Canada runs to violate it.  In real terms, Canada doing bilateral deals with other countries, especially deals potentially detrimental to the USA, only strengthens his position on dissolving the USMCA. If Canada violates the terms and spirit of the USMCA, it makes dispatch of the unliked trade agreement even easier.  Canada is helping President Trump remove the congressional justification they could use to block him.  If Canada is violating the USMCA (CUSMA), Congress is kneecapped from interference. Source: theconservativetreehouse.com (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); https://twitter.com/Geiger_Capital/status/2015924180160594345?s=20 https://twitter.com/KobeissiLetter/status/2015949123648909631?s=20  more than officially reported. Furthermore, China officially bought an additional 0.9 tonnes in December, pushing the total gold reserves to a record 2,306 tonnes. This also marked the 14th consecutive monthly purchase. In 2025, China's total reported gold purchases reached +27 tonnes. Assuming official purchases were 10% of what China is actually buying, this suggests China acquired +270 tonnes of physical gold in 2025. China is stockpiling gold like we are in a major crisis.    2025. Why hasn’t the Korean Legislature approved it?   Because the Korean Legislature hasn’t enacted our Historic Trade Agreement, which is their prerogative, I am hereby increasing South Korean TARIFFS on Autos, Lumber, Pharma, and all other Reciprocal TARIFFS, from 15% to 25%. Thank you for your attention to this matter!   DONALD J. TRUMP PRESIDENT OF THE UNITED STATES OF AMERICA Political/Rights DOGE https://twitter.com/alx/status/2015969948674203731?s=20 Geopolitical  War/Peace Medical/False Flags [DS] Agenda  https://twitter.com/VASenateGOP/status/2015208669336813823?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E2015208669336813823%7Ctwgr%5E5081d9eb1b9220fa690d082571ec929c4f0248cc%7Ctwcon%5Es1_c10&ref_url=https%3A%2F%2Fwww.thegatewaypundit.com%2F2026%2F01%2Fvirginia-democrats-now-seeking-double-their-own-pay%2F   pocket to line their own. TOTAL CON JOB! True. The Department of Justice did withdraw its request for arrest warrants against Don Lemon and four other individuals involved in the disruption of a church service in St. Paul, Minnesota, following a federal magistrate judge’s refusal to approve the related criminal complaints and an appeals court’s rejection of the DOJ’s emergency bid to compel the warrants.  While prosecutors could potentially pursue charges through alternative means, such as a grand jury, the specific action of withdrawing the warrant request aligns with the reported events https://twitter.com/mrddmia/status/2016208255677067439?s=20 https://twitter.com/EricBrakey/status/2015578832070123856?s=20 https://twitter.com/JayTownAlabama/status/2015584436230717786?s=20 According to recent data from the Giffords Law Center, the following 16 jurisdictions (15 states plus the District of Columbia) have explicit prohibitions on carrying firearms at demonstrations, protests, or licensed public gatherings. These restrictions vary by state, with some banning both concealed and open carry, while others target only one or apply under specific conditions (e.g., only for participants or permitted events). Note that laws can change, and some states have exceptions like for enhanced permit holders. State/Jurisdiction Concealed Carry Prohibited? Open Carry Prohibited? Notes Alabama Yes Yes Arkansas Yes No Applies only to participants in permitted demonstrations; enhanced CCW permittees are allowed. California No Yes Open carry banned generally. Connecticut No Yes Open carry banned generally. District of Columbia Yes Yes Florida No Yes Open carry banned generally. Hawaii Yes Yes Illinois Yes Yes Louisiana Yes No Applies to permitted demonstrations or parades. Maryland Yes Yes Mississippi Yes No Applies to permitted demonstrations or parades. Nebraska Yes No Applies at “political rallies” and fundraisers. New Jersey Yes Yes New York Yes Yes North Carolina Yes Yes Washington No Yes   https://twitter.com/EndWokeness/status/2015928285436203305?s=20 https://twitter.com/GuntherEagleman/status/2016211395273011469?s=20  gets disarmed… then shot. DHS is already tracking violent agitators who assault or obstruct officers (you know, felonies). Tom Homan pushing to make these interferers “famous” via database – names, faces, employers notified. The same crowd screaming “police state” will ignore he already assaulted officers once and walked   https://twitter.com/MrAndyNgo/status/2016235731602067586?s=20 https://twitter.com/JoeBiden/status/2016177515845283911?s=20   nation that tramples the 4th Amendment and tolerates our neighbors being terrorized. The people of Minnesota have stood strong — helping community members in unimaginable circumstances, speaking out against injustice when they see it, and holding our government accountable to the people. Minnesotans have reminded us all what it is to be American, and they have suffered enough at the hands of this Administration. Violence and terror have no place in the United States of America, especially when it's our own government targeting American citizens. No single person can destroy what America stands for and believes in, not even a President, if we — all of America — stand up and speak out. We know who we are. It’s time to show the world. More importantly, it’s time to show ourselves. Now, justice requires full, fair, and transparent investigations into the deaths of the two Americans who lost their lives in the city they called home. Jill and I are sending strength to the families and communities who love Alex Pretti and Renee Good as we all mourn their senseless deaths.   https://twitter.com/RyanSaavedra/status/2015985227798139267?s=20 https://twitter.com/JDVance/status/2015918587609772148?s=20 https://twitter.com/EricLDaugh/status/2015971665906110549?s=20 https://twitter.com/BillMelugin_/status/2016220055973855403?s=20     https://twitter.com/Recon1_ZA/status/2015778411650732184?s=20   It’s a rapid, involuntary reaction mediated by the brainstem, involving muscle tension, elevated heart rate, and adrenaline release. That repetitive exposure from them fatigues neural pathways but sustains heightened arousal, diverting cognitive resources from higher-order tasks to basic threat monitoring. It is an acute stressor, activating the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, which releases cortisol and adrenaline. Long exposure to this stuff impairs prefrontal cortex function critical for decision making. Pair this with the sheer annoyance, these tactics are a low-tech escalation of protest disruption, rooted in documented physiological responses to noise. In layman’s terms, they’re putting these officers on edge and triggering them to act. Pretti and Good was exactly what they wanted. It’s usually someone else who ends up dying and not the instigator. This is a great example. Watch the guy at the rear strike an officer against the head with an object. These officers, already on edge, are very likely to react to something like that. When someone ends up getting hurt, they’re all innocent. These events aren’t random. These are organised tactics. 80% of the people protesting aren’t aware that they’re being used by their own team as cannon fodder to generate outrage. https://twitter.com/DataRepublican/status/2015620564787105892?s=20   Tending the Soil on Chuffed. More about Tending the Soil later. What to know: the campaign is hosted by Chuffed and the first donation came from Jonny Soppotiuk, a Canada-based community organizer who is part of Chuffed leadership and specializes in fundraising. He is most likely a central figure in raising money. So, yeah. Starting to look like foreigners are playing a key role in all of this. That’s not all. I’ve put together a spreadsheet of 4000+ donors and their possible identities. https://twitter.com/davidson_f14299/status/2015874164679442499?s=20  Machine that's been running this country for decades. She's tied into the donors, the nonprofits, the consultants, the media networks — all the gears that keep the Machine turning. And look at what she just did. She tweeted out that webpage directing people to donate through a foreign‑operated platform. That's not some innocent little share. That's the Machine signaling to its own network — money pipelines, global partners, and political messaging all moving in sync. She knows exactly what she's amplifying and who benefits from it. And this isn't new for her. Look back at Russiagate. Her campaign funded the Steele dossier — the spark that set off years of investigations, headlines, and division. Even after the whole thing fell apart under scrutiny, the chaos it created was already locked in. That's how the Machine works: it doesn't need accuracy, it just needs momentum. And she's been one of the people who knows how to generate that momentum better than anyone. So where does she sit in the Machine? Right in the core. Not elected. Not accountable. Still pulling levers through the same networks she helped build. She's not operating inside the Machine — she's one of the people who designed the damn thing. And that's why her name keeps showing up. Not because she holds office. But because the Machine still runs on the structures she put in place — and every time she boosts a link, a cause, or a narrative, you can see those old gears turning all over again.  https://twitter.com/julie_kelly2/status/2015963638096429102?s=20 https://twitter.com/WarClandestine/status/2015941282237972649?s=20     President Trump's Plan  And we back you WHOLEHEARTEDLY in making it happen https://twitter.com/TriciaOhio/status/2015939758858371393?s=20   https://twitter.com/EricLDaugh/status/2015858856430055491?s=20   professional. He will continue to lead Customs and Border Patrol throughout and across the country — Mr. Homan will be the main point of contact on the ground in Minneapolis.” Hakeem Jeffries Backs Impeachment Push Against Kristi Noem House Minority Leader Hakeem Jeffries and his leadership team voiced support Tuesday for impeaching Department of Homeland Security (DHS) Secretary Kristi Noem. Nearly 150 House Democrats have sponsored articles of impeachment against Noem, first unveiled by Democratic Illinois Rep. Robin Kelly on Jan. 14, but Jeffries had not previously backed the impeachment push. Jeffries vowed Tuesday that House Democrats will launch impeachment proceedings against Noem if President Donald Trump does not fire her. Source: dailycaller.com https://twitter.com/disclosetv/status/2016203259900317988?s=20   https://twitter.com/amuse/status/2016218361844174956?s=20   Minnesota State Patrol has now been activated. They could have done this the whole time, but it wasn't until after the call between Walz and Trump, and the discovery of the Signal groups involving Minnesota government officials, that this happened.   https://twitter.com/CynicalPublius/status/2015868419187544417?s=20 https://twitter.com/derrickvanorden/status/2015808200495312963?s=20 Counterinsurgency may be defined as ‘comprehensive civilian and military efforts taken to simultaneously defeat and contain insurgency and address its root causes'. Defeat refers to actively dismantling the insurgent group’s capabilities—through kinetic operations (e.g., raids, airstrikes) to kill or capture leaders, disrupt supply lines, and degrade their fighting strength. Contain means preventing the insurgency from spreading or escalating. This could involve securing borders, isolating insurgent areas, or using psychological operations (psyops) to undermine their recruitment and propaganda. The “simultaneously” part stresses that these aren’t sequential steps; they happen in parallel. You can’t just “contain” without addressing threats, nor can you defeat an insurgency if it keeps regenerating in new areas. Key challenge: Insurgents often blend into the civilian population, making it hard to target them without collateral damage, which can create more enemies. 3. Address Its Root Causes Insurgencies don’t arise in a vacuum; they’re often driven by underlying issues like political exclusion, economic inequality, corruption, ethnic tensions, or lack of basic services. The definition insists that long-term success requires tackling these “root causes” to prevent resurgence. This might include reforms such as land redistribution, anti-corruption drives, inclusive governance, or economic development programs. Without this, military victories are temporary. For instance, historical cases like the Malayan Emergency (1948–1960) succeeded partly because British forces combined military action with resettlement programs and political concessions that addressed Malay grievances against colonial rule. Broader Context and Principles Population-Centric Approach: Modern COIN doctrine, influenced by thinkers like David Galula or modern adaptations, views the local population as the “center of gravity.” The goal is to protect civilians, gain their trust, and separate them from insurgents—often summarized as “clear, hold, build” (clear insurgents from an area, hold it securely, and build sustainable institutions). Challenges and Criticisms: COIN is resource-intensive, time-consuming, and politically fraught. It can lead to prolonged conflicts, human rights abuses, or mission creep. Critics argue it sometimes ignores cultural contexts or over-relies on foreign intervention, as seen in Vietnam or Iraq. Success Factors: Effective COIN requires unity of effort (coordination between allies), intelligence-driven operations, and adaptability. Metrics for success go beyond body counts to include governance improvements and reduced violence. In essence, this definition portrays counterinsurgency as a balanced, enduring campaign that blends force with reform to not just suppress rebellion but eliminate the conditions that sustain it.    https://twitter.com/EricLDaugh/status/2015886441063055779?s=20 patriots need all the support they can get!  Background on the “Big Beautiful Bill” and ICE Funding In 2025, Republicans passed the “One Big Beautiful Bill Act” (often referred to by President Trump as the “Big Beautiful Bill”), which allocated approximately $75 billion to Immigration and Customs Enforcement (ICE) over four years. This funding was separate from annual appropriations and effectively tripled ICE’s budget, providing a multi-year “slush fund” for immigration enforcement, including deportations.  This bill was part of Trump’s broader immigration agenda and bypassed traditional yearly funding processes, allowing ICE to operate independently of short-term congressional battles. Current Shutdown Threat and Democrats’ Strategy Democrats, led by figures like Senate Minority Leader Chuck Schumer and Sens. Patty Murray, Chris Murphy, and others, have vowed to block the Department of Homeland Security (DHS) funding bill in the Senate. This bill includes $64.4 billion for DHS overall, with about $10 billion specifically for ICE in the current fiscal year.  Why the Shutdown Won’t Defund ICE Even prominent Democrats like Sen. Murray acknowledge that a shutdown or continuing resolution (short-term funding patch) won’t restrain ICE. The agency can draw from the $75 billion already secured via the Big Beautiful Bill, allowing operations to continue uninterrupted under Trump’s “law-and-order” immigration crackdown.  A shutdown would primarily affect non-ICE parts of DHS (e.g., TSA, FEMA, Coast Guard) and other bundled departments, forcing some federal workers to go without pay while ICE remains funded and operational.  Republican Position and “Upper Hand” The White House and GOP leaders like Speaker Mike Johnson are not yielding, insisting on passing the full package without decoupling DHS funding. They view Democratic threats as ineffective since ICE’s core operations are protected by the prior bill.  The House has already passed the DHS bill with some Democratic support, putting pressure on the Senate. Republicans are framing this as Democrats prioritizing protests over essential services, giving the GOP leverage in negotiations.    https://twitter.com/AwakenedOutlaw/status/2015946190219837842?s=20   themselves, and engage in thoughtful discourse and/or express outrage against the wholesale ridiculousness of not allowing the government to do its job and protect us…and they do so for months on matters that most would never have otherwise engaged in AND would otherwise slip out of the news cycle quickly.    The Supreme Court ends up taking the case and rules (correctly) in favor of his administration. Piece by piece through this process, legal precedence is secured. Which, as it turns out, was deemed necessary to help secure the future of our Republic writ large. Lather. Rinse. Repeat. This implies that we are directly involved in an educational process, if you will, as we all progress through the realignment. Advantage: America’s future https://twitter.com/AGPamBondi/status/2015932965528764622?s=20   violent agitators. The DOJ went to court. We got a temporary stay. NOW, the 8th Circuit has fully agreed that this reckless attempt to undermine law enforcement cannot stand. 8th Circuit Court of Appeals rules in favor of Trump admin allowing ICE agents to arrest, detain, pepper-spray or retaliate against violent anti-ICE rioters, in Minneapolis, without probable cause   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");

This week, we are joined by Chris Masterjohn, PhD. Chris is a nutritional scientist, a former professor, and the founder of Mitome. With a PhD in nutritional science and years of research in mitochondrial biology, Chris's work focuses on translating peer-reviewed science into practical tools for human health. At Mitome, Dr. Masterjohn pioneered the first analysis designed to measure mitochondrial respiratory chain function directly, identifying individual energy bottlenecks and guiding personalized science-backed protocols to optimize the system responsible for over 90% of cellular energy production. His mission is to bring mitochondrial testing out of the rare disease space and into everyday health. In part 2, we discuss the biochemistry of our stress response and the potential benefits of balanced nutrition for those in psychiatric drug withdrawal. *** Thank you for being with us to listen to the podcast and read our articles this year. MIA is funded entirely by reader donations. If you value MIA, please help us continue to survive and grow. https://www.madinamerica.com/donate/ To find the Mad in America podcast on your preferred podcast player, click here: https://pod.link/1212789850 © Mad in America 2025. Produced by James Moore https://www.jmaudio.org

Disease accelerates years in a month. Cancer cells reveal which patients might be most impacted by metastasis - a diagnosis invisible on Earth. Single crystals heal themselves through mechanisms we can't explain. These aren't projections. They're validated results from 2022-2025 that made 40-year NASA veterans say they'd never seen anything like it.The economics flipped. Merck flew Keytruda 30 days, discovered a crystal form missed in a decade of labs - $20B/year by 2030, exceeding SpaceX's entire revenue. The thesis: Two paths to space affordability: cut launch costs 10x AND multiply payload value 1,000x. Do what Earth cannot do at any price.Paradigm Shifts:

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world's largest privately held pharma companies, Brian Hilberdink's journey is anything but conventional. Live from JPM 2026 in San Francisco, Biotech 2050 host Alok Tayi sits down with the President, U.S. Human Pharma at Boehringer Ingelheim to explore how frontline sales experience shaped a career now steering launches across obesity, chronic kidney disease, oncology, and rare disease. The pair dive into Boehringer's long-term, privately held model—one that reinvests nearly 30% of revenue into R&D—and the strategic thinking behind its ambitious pipeline: first-in-class breakthroughs in interstitial lung disease, major obesity programs, and upcoming waves of launches through 2027 and beyond. They also unpack the future of commercial pharma—from direct-to-consumer models and digital patient engagement to AI-powered launches and trial recruitment—plus Brian's candid views on China's innovation engine and the growing importance of rare disease. A masterclass in modern pharma leadership, portfolio strategy, and building for generations. Biography: Brian Hilberdink is an accomplished global executive with over 25 years of leadership experience in the pharmaceutical industry, currently serving as President of U.S. Human Pharma at Boehringer Ingelheim. In his role at Boehringer, he oversees several business units across multiple therapeutic areas, including cardiometabolic and renal diseases, obesity, pulmonary fibrosis (ILD), and oncology. Renowned for driving impactful results and fostering cultures of accountability and engagement, Brian consistently enhances organizational performance. Previously, Hilberdink served as Executive Vice President at LEO Pharma, where he led the North American Region and served as President of the U.S. affiliate, which became the primary growth driver for the company globally.. Earlier in his career, Hilberdink held several senior-level positions at Novo Nordisk, where he worked across multiple geographies. He was recognized for developing and executing innovative go-to-market strategies, resulting in the successful launch of multiple blockbuster therapies in the areas of obesity and diabetes.

Send us a textAre GLP-1 drugs becoming a long-term foundation of healthcare? In this clip from our episode "What JPM Signals for Healthcare in 2026", CareTalk hosts David Williams and John Driscoll discuss why GLP-1s may be evolving beyond short-term weight loss treatments.Listen to the full episode here

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of the Trade Guys, Bill and Scott discuss President Trump's tariff threats surrounding Greenland and the outcomes of the World Economic Forum in Davos. They also look at a series of new trade agreements, including a deal between China and Canada, and close by unpacking Trump's deals on pharmaceutical pricing. 

Send us a textAI, GLP-1s, federal policy, and China. Those themes dominated last week's JP Morgan Health Care Conference in San Francisco. But what, if anything are the implications for the broader healthcare world in 2026?Hosts David Williams, President of Health Business Group, and John Driscoll, Chairman of UConn Health discuss what stood out most at JPM, including why the GLP-1 wave may be entering a new phase, how Big Tech and AI are reshaping the healthcare landscape, and why China's growing presence in biotech is becoming harder to ignore.

In "Vanity Metrics Don't Move Freight: Building Real Pipeline in Freight-Tech", Joe Lynch and Jim Waters, Fractional CMO and Founder of FreightTech (marketing), discuss how marketing must shift from a tactical cost center to a strategic operating system that drives real revenue. About Jim Waters Jim Waters is a Boston-based B2B marketing executive with a proven track record of building robust sales pipelines. His passion lies in driving meaningful conversations, understanding customer pain points, and creating compelling content that generates active pipeline velocity. A results-driven innovator, Jim was an early employee at both FRAYT and Tive, where he spearheaded Global Marketing. Jim's entrepreneurial spirit led him to build successful marketing teams at Coveo, (CVO.TO), FAST (MSFT) and StreamServe (NASDAQ: OTEX). He earned an MBA from Northeastern University and is now Founder of FreighTech Advisors fractional CMO and advisor services to companies in the Logistics Technology industry. About FreighTech FreighTech is a company that delivers fractional CMO consulting, content development, marketing and advisory services specifically to logistics technology businesses. The company was founded in 2023 by Jim Waters, a logistics and supply chain marketing veteran. Key Takeaways: Vanity Metrics Don't Move Freight: Building Real Pipeline in Freight-Tech In "Vanity Metrics Don't Move Freight: Building Real Pipeline in Freight-Tech", Joe Lynch and Jim Waters, Fractional CMO and Founder of FreightTech (marketing), discuss how marketing must shift from a tactical cost center to a strategic operating system that drives real revenue. FreighTech's Specialization: Founded in 2023, FreighTech provides fractional CMO consulting and marketing advisory services specifically for logistics technology businesses. Jim Waters leverages his deep industry experience (having scaled companies like Tive and Frayt) to help growth-stage startups turn marketing from a cost center into a revenue-generating engine without the overhead of a full-time executive. Marketing as a Portfolio: Jim argues that marketing should be treated as an investment portfolio, not a one-off cost. Just like a financial portfolio or a fitness routine, it requires time and consistency. Companies often fail because they "micromanage" their marketing, expecting an immediate ROI within two weeks, rather than allowing for the 6–9 month cycle often required to see real pipeline growth. The Death of the Cold Call and the Rise of "Stalking": The traditional sales model of making 100 cold calls a day is losing effectiveness because buyers now screen calls and conduct their own research online. Joe and Jim discuss how the buying process starts long before the sales process, with potential customers "stalking" a company's content on LinkedIn, YouTube, and podcasts for up to a year before ever engaging with a salesperson. Navigating the 2026 Visibility Shift (SEO, GEO, and AEO):  Visibility in 2026 requires more than just traditional Search Engine Optimization (SEO). Jim introduces two critical new concepts: GEO (Generative Engine Optimization): Ensuring your brand is cited by AI engines like ChatGPT and Gemini as a subject matter expert. AEO (Answer Engine Optimization): Structuring content to directly answer binary buyer questions (e.g., "How do I improve ROI in logistics marketing?"). The "Revenue Engine Blueprint" Basics: Before scaling, companies must master the basics. Jim emphasizes that a "blueprint" requires a clear understanding of the Total Addressable Market (TAM) and a refined Ideal Customer Profile (ICP). Without knowing exactly who you solve problems for, adding expensive tech stacks like Salesforce or HubSpot is simply "accelerating into a wall." The Danger of "Chainsaw" Customers: Jim shares a cautionary tale from his time at Tive about a salesperson wanting to tape a high-end tracker to a chainsaw to prevent theft. While any revenue is tempting, Jim warns that chasing customers outside your ICP is not repeatable or scalable. True growth comes from "niching down" to focus on fans and specific verticals (like Pharma or Cold Chain) rather than trying to be everything to everyone. Multiplying Reach through a Distribution Engine: Content is only half the battle; the other half is a distribution engine. This involves using a "one-to-many" strategy—leveraging partners, PR, and podcasts to amplify a single piece of high-quality thought leadership. By turning one conversation into video clips, articles, and social posts, companies build the authenticity and trust necessary for modern freight-tech sales. Learn More About Vanity Metrics Don't Move Freight: Building Real Pipeline in Freight-Tech Jim Waters | Linkedin FreighTech | Linkedin FreighTech Driving Sales Pipeline with Jim Waters | The Logistics of Logistics The Key to Effective Last Mile Delivery with Jim Waters | The Logistics of Logistics Every Shipment Matters With Jim Waters | The Logistics of Logistics The Logistics of Logistics Podcast If you enjoy the podcast, please leave a positive review, subscribe, and share it with your friends and colleagues. The Logistics of Logistics Podcast: Google, Apple, Castbox, Spotify, Stitcher, PlayerFM, Tunein, Podbean, Owltail, Libsyn, Overcast Check out The Logistics of Logistics on Youtube

Patrick McKenzie (patio11) is joined by Ruxandra Teslo to discuss why drug development keeps getting more expensive despite revolutionary new treatment modalities from GLP-1 agonists to gene therapies. They discuss Eroom's Law (Moore's Law in reverse) and Ruxandra's Common Technical Document Project, which aims to build the "Stack Overflow of clinical development" by making regulatory submissions publicly accessible. This will fill a present hole in the education of researchers, lower barriers for small biotechs, and accelerate drug discovery.–Full transcript available here: https://www.complexsystemspodcast.com/ruxandra-teslo/ –Sponsor: FramerBuilding and maintaining marketing websites shouldn't slow down your engineers. Framer gives design and marketing teams an all-in-one platform to ship landing pages, microsites, or full site redesigns instantly—without engineering bottlenecks. Get 30% off Framer Pro at framer.com/complexsystems.–Links:Eroom's Law (original paper): https://www.nature.com/articles/nrd3681Ruxandra's writing: https://www.writingruxandrabio.com/ Ross Rheingans-Yoo on drug development: https://open.spotify.com/episode/4GiO0KYqxJNCIdltCyhN6m?si=2znQniZ3RXKuX8keNcwWtw Ben Reinhardt on science and development: https://open.spotify.com/episode/0GHegWgLSubYxvATmbWhQu?si=pVCJVITYTqaq65BiST2d0Q–Timestamps:(00:00) Intro(00:56) Challenges in biopharma productivity(03:12) Understanding clinical development(04:59) The role of basic science in drug development(07:39) Clinical development process explained(09:25) Issues in clinical trials and development(19:33) The role of information in clinical trials(20:30) Sponsor: Framer(21:42) The role of information in clinical trials (continued)(32:55) Proposed solutions for clinical development(40:31) Consultant opinions and regulatory documents(41:28) Streamlining the regulatory process(43:06) Understanding FDA interactions(45:35) Building a public library of regulatory documents(48:18) Encouraging novel approaches in biotech(50:06) Addressing risk aversion in the industry(51:52) Analyzing FDA consistency and reviewer heterogeneity(01:02:15) The importance of courage in professional growth(01:06:39) Supporting young professionals and catalyzing change(01:16:14) Wrap

Are Trump's pharmaceutical policies a seismic revolution, or just hot air? Will he succeed in lowering drug prices in 2026? Will manufacturing shift to the US? And how will all of this impact Europe and China? ING's Diederik Stadig and Stephen Farrelly answer these questions and more in this week's THINK aloud.

Aizon.ai provides an AI software platform for the pharmaceutical and biotech industries to optimize manufacturing processes, ensure GxP compliance, and improve product quality. Their top outcomes include financial savings and improved operational efficiency for clients. Aizon's ability to optimize manufacturing production and quality in highly regulated industries by providing real-time visibility and predictive insights while ensuring GxP compliance. The AWS case study details how a pharmaceutical company utilized Aizon's AI platform to achieve double-digit yield improvements through clinical process optimization. AWS Hosts: Nolan Chen & Gokhul Srinivasan https://aws.amazon.com/solutions/case-studies/aizon-case-study/https://aws.amazon.com/marketplace/seller-profile?id=5bb4e9b6-8a87-40d9-aea5-adc6ebcad7c0https://www.aizon.ai/success-storiesEmail Your Feedback: rethinkpodcast@amazon.com

Michael Kramer was 19 when cancer ambushed his life. He went from surfing Florida beaches to chemo, radiation, and a bone marrow transplant that left him alive but carrying a chronic disease. He had necrosis in his knees and elbows, lost his ability to surf for years, and found himself stuck in hospitals instead of the ocean. Yet he adapted. Michael picked up a guitar, built Lego sets, led support groups, and started sharing his story on Instagram and TikTok.We talk about masculinity, identity, and what happens when the thing that defines you gets stripped away. He opens up about dating in Miami, freezing sperm at a children's hospital, awkward Uber-for-sperm moments with his brother, and how meditation became survival. Michael lost his father to cancer when he was a teen, and that grief shaped how he lives and advocates today. He is funny, grounded, and honest about the realities of survivorship in your twenties. This episode shows what resilience looks like when you refuse to walk it off and choose to speak it out loud instead.RELATED LINKSMichael Kramer on InstagramMichael Kramer on TikTokMichael and Mom Inspire on YouTubeAshlee Cramer's BookUniversity of Miami Sylvester Comprehensive Cancer CenterStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if everything you were told about vaccine safety and public health was built on incomplete science? Why are parents and doctors afraid to ask basic questions without being labeled or silenced? In this episode, we confront the uncomfortable truths behind vaccines, the CDC, and the future of medical freedom. Thank you to our sponsors! Sunlighten Sauna: https://get.sunlighten.com/axepodcast Manukora Manuka Honey: https://manukora.com/axe Watch The Dr. Josh Axe Show every Monday & Thursday on YouTube: https://www.youtube.com/@drjoshaxe

In this episode of Off Script, we continue our conversation with David Grote, vice president of strategy at GrayMatter Partners, focusing on the execution challenges that will define the success of today's pharmaceutical manufacturing investment boom. David explores the growing tension between speed, quality, and cost as companies race to bring new facilities online, and explains how early collaboration with regulators can help accelerate validation without sacrificing compliance or long-term resilience. He also discusses the strategic decisions that separate proactive manufacturers from reactive ones, the lasting impact this investment cycle will have on U.S. manufacturing footprints, and the expanding set of options that could open new opportunities for smaller companies.

Generative AI is moving fast—and in pharma, it's no longer just a buzzword. In this episode of The Effective Statistician Podcast, I speak with Manuel Cossio about how Generative AI is already being applied in real-world pharma settings, where it's delivering value today, and what still needs careful consideration in regulated environments. Manuel brings a unique hybrid background, combining molecular biology, genetics, pharma experience, and deep AI engineering expertise. He works at the cutting edge of AI in clinical development, including agentic systems, human-in-the-loop approaches, and large-scale document automation. This conversation goes well beyond theory. We focus on practical use cases, real limitations, and how statisticians, programmers, and data scientists can responsibly use GenAI to become more effective.

On this Salcedo Storm Podcast:Travis Morgan covers legal issues for the Texas scorecard.

America Out Loud PULSE with Dr. Vaughn & Dr. Tankersley – Basically, it was an inversion of the prior propaganda, which only benefited BigAg and PHARMA. As Sec. Kennedy summarized- "We need to eat real food." We spend $5 trillion annually on health (40 cents for every tax dollar goes to this) which is three times the amount that European countries. PUBLIC HEALTH HAS...

America Out Loud PULSE with Dr. Vaughn & Dr. Tankersley – Basically, it was an inversion of the prior propaganda, which only benefited BigAg and PHARMA. As Sec. Kennedy summarized- "We need to eat real food." We spend $5 trillion annually on health (40 cents for every tax dollar goes to this) which is three times the amount that European countries. PUBLIC HEALTH HAS...

Daniel Garza had momentum. Acting roles, directing gigs, national tours lined up. Then anal cancer stopped everything. Radiation wrecked his body, stripped him of control, and left him in diapers, staring down despair. His partner, Christian Ramirez, carried him through the darkest nights, changed his wounds, fought hospitals, and paid the price with his own health. Christian still lives with permanent damage from caregiving, but he stayed anyway.Together they talk with me about masculinity, sex, shame, friendship, and survival. They describe the friendships that vanished, the laughter that kept them alive, and the brutal reality of caregiving no one prepares you for. We get into survivor guilt, PTSD, and why even rocks need rocks. Daniel is now an actor, director, and comedian living with HIV. Christian continues to tell the unfiltered truth about what it takes to be a caregiver and stay whole. This episode gives voice to both sides of the cancer experience, the survivor and the one who stands guard. RELATED LINKSDaniel Garza IMDbDaniel Garza on InstagramDaniel Garza on FacebookChristian Ramirez on LinkedInLilmesican Productions Inc (Daniel & Christian)Stupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After years of volatility, pharmaceutical manufacturing is entering a new investment cycle, with hundreds of billions of dollars flowing into U.S. facilities. The surge promises expanded capacity, but also raises questions about workforce availability, infrastructure readiness, and long-term execution. In this episode of Off Script, we spoke with David Grote, vice president of strategy at GrayMatter Partners, about what this wave of funding means in practice. The conversation explores where investment is concentrating, how competition for skilled talent is shaping project timelines, the strain on shared resources, and why flexible facility design will be critical to sustaining growth beyond today's political and economic cycle.

China has moved from a fast-following biotech market to a source of globally competitive innovation, according to Josh Smiley, president and chief operating officer of Zai Lab. Speaking on The Top Line podcast, Smiley traces the country’s evolution over the past two decades, pointing to regulatory harmonization, expanded national insurance coverage and deepening R&D capabilities as key drivers. He said the most recent wave of Chinese biotechs is no longer focused solely on domestic opportunities but on first- or best-in-class medicines that can compete worldwide, particularly in oncology and immunology. Smiley also details how Zai Lab blends China’s patient access and development speed with global clinical and regulatory standards, a model he says has helped accelerate programs such as Zai’s DLL3-targeted antibody-drug conjugate for small cell lung cancer into late-stage trials. As China-sourced deals now account for a growing share of global biotech partnerships, Smiley argues companies that integrate China early — without treating it as a standalone market — will have a strategic edge. The conversation offers a candid look at what’s next for Zai Lab and why China’s expanding role in drug innovation is likely to reshape the global pipeline for years to come.See omnystudio.com/listener for privacy information.

How American oil companies are responding following U.S. action in Venezuela? And why were Constellation investors happy with lower beer sales? Plus, how can a big pharma deal help Eli Lilly compete in a new treatment area? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

How American oil companies are responding following U.S. action in Venezuela? And why were Constellation investors happy with lower beer sales? Plus, how can a big pharma deal help Eli Lilly compete in a new treatment area? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

(0:00) Commerce Secretary Howard Lutnick tells a hilarious Air Force One story (2:24) Chamath intros Secretary Lutnick (7:28) Full scope of the Commerce Department (12:59) How Trump's tariff agenda was planned and executed, how it's going (19:50) US-Japan trade deal, China's chaos-to-prowess strategy (36:54) Why the India deal has not yet happened (43:48) Pharma deals, lowering costs for Americans (53:28) Focus on fraud, immigration, gold cards (1:03:48) GDP: Could we see 5 or 6% growth in 2026? (1:11:49) How the Trump Admin revamped the CHIPS Act, Nvidia deal Follow Secretary Lutnick: https://x.com/howardlutnick Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect

After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved. A tough biotech investing environment, aggressive direct-to-consumer drug marketing and sweeping U.S. policy changes reshaped the landscape last year. Many of those pressures are expected to persist into 2026, even as early signs point to a thaw in venture capital. At the same time, the industry is testing whether DTC drug sales can meaningfully affect pricing for patients and whether broad manufacturing onshoring goals can realistically apply to advanced therapies like cell and gene treatments and radiopharmaceuticals. In this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits down with three biopharma CEOs to unpack what defined 2025 and what comes next. He’s joined by Thijs Spoor, CEO of Perspective Therapeutics; Brian Culley, CEO of Lineage Cell Therapeutics; and Rich Daly, CEO of Catalyst Pharmaceuticals. Together, they tackle issues from DTC sales and onshore manufacturing to drug pricing, regulatory uncertainty at the FDA and the broader innovations the leaders are most excited about this year. To learn more about the topics in this episode: 2026 forecast: After a surge of M&A in Q4, will the trend continue? Editor's Corner: Fierce Biotech's 10 most-read stories of 2025 What a year: Here are the stories that captivated our audience in 2025 Editor's Corner: The top 10 Fierce Pharma Marketing stories of 2025 2026 forecast: Pharma clicks with patients as direct sales model shifts marketing strategies See omnystudio.com/listener for privacy information.

What does it take to run a truly effective Functional Service Provider (FSP) model in today's biopharma landscape? From harmonizing global teams to embedding innovation into daily delivery, FSP engagement is more than a resourcing solution — it's about strategic collaboration and approaches that accelerate delivery. The Syneos Health Podcast: Functionally Speaking series explores the nuances that make these models work. In this episode of the Functionally Speaking series, host Lynn Hamilton sits down with Wayne Wise, Vice President of Clinical Operations at Syneos Health, to explore the real-world shifts happening in large pharma partnerships. With nearly two decades at the company and deep cross-functional experience, Wayne shares how agility, strategic governance and trust-based team leadership are reshaping FSP delivery models. From evolving CRA roles and co-created governance to the increasing use of AI, Wayne offers a firsthand look at how functional teams are adapting in real time to operational and strategic shifts across the industry.  You will walk away with insights on:Moving beyond transactional models to strategic, insight-driven partnershipsBuilding agile teams that thrive amid complexityTransforming governance to focus on action, not just KPIsHow the CRA role is evolving with tech-enabled site engagementWhat sponsors can do to unlock value through co-creationThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Today's guest is Vaithi Bharath, Associate Director of Data Science & AI Solutions at Bayer. Bharath joins Emerj Editorial Director Matthew DeMello to break down why clinical R&D timelines often slip for reasons that have little to do with model performance. Rather, delays compound when data moves across fragmented systems, teams rely on slow handoffs, and validation requirements turn minor adjustments into major cycle-time hits. He walks through where decision-making slows from data capture through database lock, and what it takes to accelerate workflows without replacing a validated environment. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! This episode is sponsored by AnswerRocket.

Trevor Maxwell lived the archetype of masculinity in rural Maine. Big, strong, splitting wood, raising kids, and carrying the load. Then cancer ripped that script apart. In 2018 he was bedridden, emasculated, ashamed, and convinced his family would be better off without him. His wife refused to let him disappear. That moment forced Trevor to face his depression, get help, and rebuild himself. Out of that came Man Up To Cancer, now the largest community for men with cancer, a place where men stop pretending they are bulletproof and start being honest with each other.Eric Charsky joins the conversation. A veteran with five cancers, forty-nine surgeries, and the scars to prove it, Eric lays out what happens when the military's invincible mindset collides with mortality. Together, we talk masculinity, vulnerability, sex, shame, and survival. This episode is blunt, raw, and overdue.RELATED LINKSMan Up To CancerTrevor Maxwell on LinkedInDempsey CenterEric Charsky on LinkedInStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Advancing longevity research is about honoring the value of life—and translating that respect into evidence-based prevention. If healthcare is judged by life expectancy + quality of life, longevity medicine may be one of the most meaningful metrics we can pursue: extending health span through early detection, validated biomarkers, and interventions that scale.This unforgettable Expert Panel from the 4th annual Medical Innovation Olympics (#MIO2025) convened all-star global leaders in Longevity and Preventive Medicine who separated hype from reality and outlined what it will take to bring longevity into mainstream care - rigorously, ethically, and accessibly.Topics include: breakthroughs (including epigenetic approaches pointing toward functional restoration of eyesight), biomarkers/endpoints as the “keystone” for faster trials, the TAME (Targeting Aging with Metformin) concept, and the role of standards, education, trust, and shared responsibility—keeping dignity central.Panelists:Dr. David Barzilai (Harvard Medical School; Geneva College of Longevity Science, GCLS) • Dr. Dominik Thor (President, GCLS) • Dr. Mishkat Shehata (Emirates Lifestyle & Longevity Medicine Society) • Keith Comito (Lifespan Research Institute) • Dr. Uma Senthilkumar (Three Five Revive)

In this episode, I talked to Dr. Alex Zhavoronkov, CEO of Insilico Medicine, about using AI to generate small molecules for future drugs/therapies, pharma superintelligence, automation of drug discovery, China potentially beating US in biotech innovation, aging, and other funny things, like his head transplant video. ---------------------------------------------------------------Thanks to the sponsors:Audible: Use my link for a 30-day free trial: http://audibletrial.com/diamondgoatNewsly: https://newsly.mepromo code to receive a 1-month free premium subscription: EARLYMORNING Libysn: https://libsyn.compromo code: DG Dubby Energy: https://www.dubby.ggpromo code for 10% off: DIAMONDGOATOpus Clips:  https://www.opus.pro/?via=diamondgoat----------------------------------------------------------------------------------Listen on:Podcast website: https://www.spreaker.com/podcast/dg-early-morning-show--5943922Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeOPodcast YT channel clips: https://www.youtube.com/@dgearlymorningshowTiktok: @dgearlymorningshowApple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c  Goodpods: https://goodpods.com/podcasts/dg-early-morning-show-211830RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4rBreaker: https://www.breaker.audio/dg-early-morning-showReason: https://reason.fm/podcast/dg-earlymorning-show--------------------------------------Check out my other stuff:Instagram: @itzdiamondgoatTwitter: @lildiamondgoatMain YT channel: youtube.com/diamondgoatTiktok: @lildiamondgoatSoundcloud: @Lil DiamondgoatSpotify: @Lil DiamondgoatMerch store: https://diamondgoat.creator-spring.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/dg-early-morning-show--5943922/support.

The Nurses Report on America Out Loud with Nicole, David & Ashley – A global pharmaceutical giant's China operation descends into bribery, espionage, and hidden-camera scandal, exposing familiar patterns of corporate corruption, regulatory failure, and human cost as whistleblowers, executives, and investigators collide with state power and unchecked pharmaceutical influence...

The Nurses Report on America Out Loud with Nicole, David & Ashley – A global pharmaceutical giant's China operation descends into bribery, espionage, and hidden-camera scandal, exposing familiar patterns of corporate corruption, regulatory failure, and human cost as whistleblowers, executives, and investigators collide with state power and unchecked pharmaceutical influence...

► Jetzt von der einmaligen Rendite-Spezialisten-Neujahrsaktion profitieren: http://rendite-spezialisten.de/vorteil - 30 Tage Geld-Zurück-Garantie
 Wir starten mit Pauken und Trompeten in das Jahr 2026. Heute möchte ich gemeinsam mit euch einen Deep Dive in Novo Nordisk machen. Es ist kein unrealistisches Szenario, dass sich die Aktie in diesem Jahr verdoppelt oder zumindest mehr als fünfzig Prozent an Wert gewinnt. Wichtig vorab der Disclaimer: Ich bin selbst mit einer Zockerposition investiert und wünsche mir daher, dass genau das eintritt, was ich im Folgenden bespreche.
 ► Hole dir jetzt deinen Zugang zur brandneuen BuyTheDip App! Jetzt anmelden & downloaden: http://buy-the-dip.de
 ► An diese E-Mail-Adresse kannst du mir deine Themen-Wünsche senden: podcast@lars-erichsen.de
 ► Meinen BuyTheDip-Podcast mit Sebastian Hell und Timo Baudzus findet ihr hier: https://buythedip.podigee.io
 Viel Freude beim Anhören. Über eine Bewertung und einen Kommentar freue ich mich sehr. Jede Bewertung ist wichtig. Denn sie hilft dabei, den Podcast bekannter zu machen. Damit noch mehr Menschen verstehen, wie sie ihr Geld mit Rendite anlegen können.
 ► Mein YouTube-Kanal: http://youtube.com/ErichsenGeld
 ► Folge meinem LinkedIn-Account: https://www.linkedin.com/in/erichsenlars/
 ► Folge mir bei Facebook: https://www.facebook.com/ErichsenGeld/
 ► Folge meinem Instagram-Account: https://www.instagram.com/erichsenlars
 Die verwendete Musik wurde unter www.soundtaxi.net lizenziert. 
Ein wichtiger abschließender Hinweis: Aus rechtlichen Gründen darf ich keine individuelle Einzelberatung geben. Meine geäußerte Meinung stellt keinerlei Aufforderung zum Handeln dar. Sie ist keine Aufforderung zum Kauf oder Verkauf von Wertpapieren.
 Zum Zeitpunkt der Erstellung dieses Beitrags war der Autor, Lars Erichsen, in folgenden der besprochenen Finanzinstrumente selbst investiert: Novo Nordisk. Geplante Änderungen: Keine. Weitere Informationen entnehmen Sie bitte unserem Transparenzhinweis zum Umgang mit Interessenskonflikten: https://www.lars-erichsen.de/transparenz-und-rechtshinweis

In this conversation, career ownership coach Maja Taylor shares powerful insights on what it truly means to take control of your professional future. She talks about helping leaders and professionals explore new career paths, including entrepreneurship, so they can maximize their potential and build careers that fully align with their goals and values. Maja encourages listeners to regularly review their career direction, consider alternative income streams and stay open to possibilities that may lead to greater fulfillment and independence. Employee Engagement and the Need for Better Guidance Michael discusses the growing disconnect many employees feel in today's workplace and highlights how small businesses and leaders can play a pivotal role in guiding their teams toward greater engagement and clarity. He emphasizes the value of career exploration and meaningful conversations that help individuals uncover interests, strengths and untapped potential. Michael also shares personal stories about stepping into new roles without a perfect plan and learning through adaptability, curiosity and experience. Navigating Burnout and Workplace Uncertainty Maja speaks candidly about the rising rates of burnout she sees among clients, driven by layoffs, constant change and market instability. She explains how her coaching practice supports individuals during these challenging transitions by helping them rediscover confidence, purpose and possibility. Maja also reflects on her own journey from science to HR to leadership coaching, revealing how each chapter deepened her passion for helping others achieve greater self sufficiency and work life balance. Corporate Experience as a Launchpad for Entrepreneurship Michael reminds listeners that entrepreneurship is rarely about starting from zero. Skills gained in corporate environments, from operational insight to relationship building, can become powerful assets when launching a business. He encourages people to recognize the value of their existing expertise and leverage it instead of discounting it. Career Coaching for the Shift Into Business Ownership Maja outlines her approach to coaching professionals who are evaluating entrepreneurship, especially those who feel drained by corporate roles or stuck in burnout cycles. She uses assessments to help clients recognize their strengths and potential, and stresses the importance of being open minded as they explore ownership opportunities. Michael adds that many people underestimate their abilities due to work environments that suppress creativity and curiosity. Curiosity as a Catalyst for Breakthroughs Michael shares a personal story about taking a personality assessment with his former CEO and discovering they shared the same profile. The experience reminded him that curiosity is a powerful driver of self awareness and growth. He encourages listeners to lean into curiosity as a tool for breakthroughs, career shifts and life changing clarity. Goal Setting, Reflection and a Free DISC Assessment Maja talks about the impact of written goals, noting that only a small percentage of people write down their goals, yet nearly all who do achieve them. She offers a complimentary executive DISC assessment to help listeners better understand their personality patterns and career strengths. Michael encourages everyone to take advantage of the offer and reminds listeners that Maja's contact information and social links are included in the show notes below.   Maja Taylor is a Career Ownership Coach with The Entrepreneur's Source, where she guides people who are ready to step outside the traditional job market and into new possibilities. She supports clients as they explore entrepreneurship, business ownership, investments, licensing, and franchising, helping them design a career path that aligns with their values, strengths and long term vision. Maja is driven by a deep passion for personal transformation and lifelong learning. She thrives on watching clients experience those pivotal AHA moments when they realize what they are truly capable of. Her mission is to help people rise to their full potential by building careers and businesses that reflect who they are and the life they want to create. With a foundation in science education and talent development, Maja has worked across Europe and the United States in global organizations as a team leader, scientist, strategic HR professional, trainer, coach and mentor. She brings a unique blend of analytical thinking, people development expertise, and business strategy to every client engagement. Her work focuses on helping individuals grow their dreams, wealth and personal equity as they move toward self sufficiency and higher levels of fulfillment and success. Background Overview • Business Owner and Certified Professional Coach • Global Talent, Learning and Engagement roles in Pharma and Biotech • Management consulting experience with Fortune 500 organizations • Scientific and HR leadership roles in manufacturing and environmental industries • Education: BS in Pharmacy, University of Applied Sciences, Wiesbaden, Germany • Credentials: Certified Coach, Human Resources Professional, Leadership Trainer and Facilitator; certified in DiSC, 360 assessments and multiple professional development tools Connect with Maja Website: www.majataylor.esourcecoach.com Email: majataylor@esourcecoach.com LinkedIn: https://www.linkedin.com/in/majataylor/ Facebook: https://www.facebook.com/majataylorcoach Instagram: https://www.instagram.com/majataylorcoach For your audience, add to captions, free offer – DiSC assessment with debrief - a $200 value – if your listeners reach out to me on social media/LI/Insta/FB/ or my website and book a call at www.majataylor.esourcecoach.com

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jim Gale, Founding Partner & Managing Director at Signet.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: The origins of growth equity in private equity and how it led to the founding of Signet, a fund built on deep domain expertise. Why private equity is a growing asset category but still remains undervalued and under appreciated. How the nature of the companies Signet invests in has evolved over the last twenty five years, while the fundamental principles of building a strong business remain the same. How the “picks and shovels” strategy of investing in tools, services and infrastructure has consistently served them well. Jim's assessment criteria when evaluating new opportunities after seventy deals, including the key question… can we institutionalise an entrepreneur led business. How higher interest rates and economic uncertainty constrain biopharma and biotech, and how that impacts investment dollars flowing into pharma services, along with deal flow, valuation and structure. James “Jim” Gale is the Founding Partner and Managing Director of Signet Healthcare Partners, a New York based healthcare growth equity firm specialising in pharmaceutical services, specialty pharma and medical technology. With more than thirty five years of investing and finance experience, Jim has built a deep track record backing companies involved in formulation, development, manufacturing and commercialisation across the world.   At Signet, Jim has led investments across the pharma services value chain, including platforms in sterile fill finish, complex formulations, biologics development and specialty generics. His current and recent board roles include Ascendia Pharmaceutical Solutions, NorthX Biologics, RK Pharma, Bionpharma, Chr Olesen Synthesis, Pharma Nobis, Juno Pharmaceuticals and Lee's Pharmaceutical. He also serves as Chairman of Bionpharma and is a director of Knight Therapeutics.   Jim holds an MBA from the University of Chicago Booth School of Business.   Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center. After all, why spend millions trying to develop novel medications in the U.S. when Chinese firms have probably already done it for you? See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

One on One Video Call W/George https://tidycal.com/georgepmonty/60-minute-meetingSupport the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USIn this powerful episode of the True Life Podcast, host George Monty delivers a hard-hitting “daily transmission” exposing how corporations and systems deliberately manufacture scarcity to drive profits, control populations, and prevent true abundance from reaching everyday people. Drawing on real-world examples from food, housing, medicine, and more, George reveals the patterns of consolidation, surplus destruction, and artificial shortages that keep society desperate and divided. He calls for recognition, documentation, and rebellion against this “scarcity weapon,” urging listeners to investigate local resources and demand the withheld plenty. This episode is a wake-up call to see beyond the narratives of inflation and supply chain issues to the engineered theft of abundance.Host: George MontyPodcast: True Life PodcastDuration: Approximately 10-15 minutes (based on transcript length)Release Date: Estimated based on content references (late 2025)Listen Here: Explore more episodes and connect with George Monty on the TrueLife platform. Key Timestamps & HighlightsGeorge's monologue flows as a continuous narrative, but we've broken it down into thematic sections with approximate timestamps for easy navigation:•  00:00 - 01:00: The Illusion of Struggle George opens by challenging the narrative that you're failing—it's engineered starvation in abundance. He prompts listeners to check their finances and see how earnings vanish despite higher pay, labeling it “2025's manufactured scarcity” designed for control and extraction.•  01:00 - 02:30: From Ancient Famines to Modern Engineering Contrasting natural famines with today's deliberate hunger, George highlights U.S. food production capacity (enough for 10 billion people) versus 34 million facing food insecurity amid record corporate profits.   He exposes the “machine that weaponizes emptiness.” •  02:30 - 04:00: Food Shortages Exposed•  2024 egg shortage: Not avian flu, but corporate consolidation by Cal-Maine Foods (20% market control), leading to tripled prices and $535 million in profits. •  2022-2024 baby formula crisis: Abbott's monopoly (43% market) caused shutdowns, boosting stock 34% while parents turned to black markets. https://www.theguardian.com/us-news/2025/apr/09/doj-egg-prices-rise-cal-maine-profits•  04:00 - 05:00: Housing and Tech Hoarding•  Housing crisis: 16 million vacant homes in the U.S. versus over 600,000 homeless, as empty properties prove more profitable. •  2025 semiconductor shortage: TSMC's alleged deliberate restrictions via leaked emails to maintain pricing, with chips stockpiled while car prices soar.  (Note: Related to trade secret leaks; broader shortage context available.)https://unitedwaynca.org/blog/vacant-homes-vs-homelessness-by-city/•  05:00 - 06:30: Surplus Destruction and Corporate Mandates George uncovers patterns of destroying goods under USDA/EPA/FDA protocols lobbied by corporations.  He cites the 2024 NASS report (Appendix G, p. 847) on 2.3 billion pounds of produce destroyed to avoid “market destabilization.”  Kroger's 2019 leaked memo advocates “optimal scarcity ratios” for urgency buying. https://www.usda.gov/about-usda/news/press-releases/2023/09/20/usda-expands-efforts-prevent-and-reduce-food-loss-and-wastehttps://www.nass.usda.gov/Charts_and_Maps/Crop_Progress_&_Condition/2024/index.phphttps://www.nationofchange.org/2024/09/03/corporate-greed-exposed-kroger-admits-to-price-gouging-on-milk-and-eggs-amid-antitrust-trial/•  06:30 - 08:00: The Scarcity Playbook Step-by-step breakdown: Consolidate supply, engineer shortages (restrict, destroy surplus), profit from desperation. Blame shifts to weather or labor, not architects.•  08:00 - 10:00: Historical and Ongoing Examples•  2008 housing crisis: Banks held 3.5 million foreclosures as “shadow inventory” to keep prices high. https://en.wikipedia.org/wiki/Subprime_mortgage_crisis•  2020 toilet paper: Procter & Gamble and Georgia-Pacific (55% control) restricted distribution for 300% price surges at 64% capacity. https://www.resourcewise.com/market-watch-blog/are-we-really-running-out-of-toilet-paper-in-the-covid-crisis•  2021 lumber: Weyerhaeuser and West Fraser (40% control) quadrupled prices with underused mills. https://markets.businessinsider.com/news/stocks/lumber-prices-hit-record-highs-soaring-past-year-2021-4-1030299977•  2023 prescription drugs: Wholesalers like McKesson, Cardinal, and AmerisourceBergen (95% control) restrict insulin ($2 production cost) amid shortages. https://www.mmm-online.com/home/channel/drug-shortages-in-america/•  2025 water: Nestlé, Coca-Cola, Pepsi (75% bottled water) amid contaminated public supplies. https://www.grandviewresearch.com/industry-analysis/bottled-water-market•  10:00 - 11:30: Broader Patterns of Waste Amazon destroys 2 million unsold products yearly for scarcity pricing.  Pharma discards effective expired meds.  Energy firms flare gas for 10 million homes.  McKinsey's 2023 report recommends 15-20% below-demand inventory for margins.  Supply chain “disruptions” post-2020? Traffic normalized by Q3 2021, but prices stayed high via throttling. https://www.ethicalconsumer.org/ethical-campaigns-boycotts/amazons-burning-approach-unsold-returned-productshttps://pmc.ncbi.nlm.nih.gov/articles/PMC10834166/

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Bruce E. Brown, a seasoned sales professional with over 20 years in pharma who made a rare and successful transition into medical device sales as an independent 1099 distributor. Bruce shares how he broke away from the corporate structure, built his own LLC, and created a sustainable business by representing multiple product lines. He reveals unconventional but effective strategies for gaining access to surgeons and hospitals, lessons learned from the opioid era, and the realities of commission-only sales. This candid conversation offers a behind-the-scenes look at what it truly takes to survive, grow, and thrive as an independent medical sales professional.   Connect with Bruce E. Brown: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »  

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this solo episode, Shintaro Higashi breaks down five key lessons he's learned from decades of running and consulting for martial arts dojos, including NYC's Kokushi Budo Institute and Kano Martial Arts. From the power of soft skills to safety, cleanliness, and even why black belts should pay, this episode offers real-world dojo business insights for gym owners, instructors, and aspiring martial arts entrepreneurs.00:00 Introduction & Dojo Background01:00 Starting Kano Martial Arts & Consulting Experience02:00 Lesson 1: Soft Skills Matter More Than Credentials04:00 Applying Sales Techniques from Pharma to Martial Arts04:30 Lesson 2: Safety Is the Top Priority05:30 Risk Management & Eliminating Dangerous Techniques06:00 Why Safety Supports the Growth of Judo06:30 Lesson 3: Cleanliness & Hygiene Systems07:30 Enforcing Hygiene Rules & Student Accountability08:30 Lesson 4: Most Students Aren't Competitive Athletes09:30 Understanding Your Student Base & Why They Train10:30 Building an Inclusive, Supportive Dojo Culture11:30 Lesson 5: Even Black Belts Should Pay12:30 Retention Risks from Non-Paying Advanced Students13:30 Supporting Other Gyms as a Paying Visitor

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here! Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeThe ultimate unholy union is government and healthcare. President Trump has put out some words on government and healthcare, and President Trump, is a good friend of big Pharma.Episode Links:Democrat Senator Peter Welch on Obamacare: "We did fail to bring down the cost of healthcare."American doctor goes over how Barack Obama destroyed American HealthcareObamacare is only 7% of Americans. Literally almost 100% of Americans need relief from their health care policy premiums, not just 7%. We need to have free market solutions that bring down the cost of health care for every American, not just the 7%.The Danish Cow Crisis: Bill Gates, “Bovaer,” and the War on Nature. In Denmark, farmers are raising alarms after a new climate-driven feed additive called Bovaer became mandatory on October 1, 2025.Virtually everything that Obama promised about Obamacare was a lie. Now the country is stuck dealing with the ramifications. Instead of taking responsibility, Democrats have shut down the government and are demanding that Republicans fix what they broke.

On this Christmas Eve edition of Badlands Daily, CannCon and Ashe in America take to the mic for a spirited, heartfelt, and wide-ranging conversation as they close out the holiday week with the Badlands community. The show blends festive moments with hard-hitting commentary, touching on government overreach, Big Pharma corruption, taxpayer-funded research scams, and the broader push to “equalize” America at the expense of its people. The hosts engage directly with the audience through rants and shout-outs, reflect on the year that was, and discuss ongoing investigations, election integrity issues, and the growing ability to speak more openly as censorship loosens. Along the way, they share holiday wishes, upcoming programming notes, and gratitude for the Badlands family that continues to show up every day. A Christmas Eve broadcast that balances humor, conviction, and community, this episode captures the spirit of Badlands Daily - truth-seeking, unapologetic, and rooted in faith, freedom, and fellowship.

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Eastman Kodak Company is ready for its closeup. The 130-year-old film company made big moves this year to bulk up its balance sheet and push into a brand new field - pharmaceuticals. Kodak completed a pension reversion in November, which unlocked $1 billion. The funds create a new pension fund, bringing debt down to $200 million, and put $300 million in cash on the balance sheet. The goal now - innovate. Kodak has always been a chemical company. Executives are using that expertise to move into the pharmaceutical industry. FOX Business's Lydia Hu speaks with Eastman Kodak Company executive chairman and chief executive officer Jim Continenza about how, while the company is still focused on film, it believes it has the expertise and infrastructure to grow by delving into pharmaceuticals. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Join Eric, @EnglishNick67, @ShelleyWynter1, Steffan Pappas, @DrJoeEsposito, Santa, @TimAndrewsHere, @Autopritts, @JaredYamamoto, Greg, and George LIVE on 95.5 WSB from 3pm-7pm as they celebrate a merry Christmas during their very last show of the year with songs, trivia, laughter, joy and more! *New episodes of our sister shows: The Popcast with Tim Andrews and The Nightcap with Jared Yamamoto are available as well!

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Allie interviews Dr. Josef Witt-Doerring, a psychiatrist and former FDA drug safety officer. He unveils the truth about Big Pharma and the detrimental side effects of medications for mental illnesses. SSRIs cause more harm than good; they blunt emotions, breed dependency, and often backfire long-term. Dr. Witt-Doerring advises patients to pursue holistic health that includes a balanced diet, sleep, exercise, and therapy. He and his wife have started TaperClinic, where they help people come off medications and find real solutions to their problems. Join us for an eye-opening discussion about the dark side of the pharmaceutical industry. Check out more about Dr. Witt-Doerring's TaperClinic here: ⁠taperclinic.com⁠ Buy Allie's book "Toxic Empathy: How Progressives Exploit Christian Compassion": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.toxicempathy.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Timecodes: (00:00) Intro (09:45) Misdiagnosing Mental Illness (19:20) Drug Safety Officer (25:05) Corruption in Medical Academia (27:50) Wake-Up Call (34:35) Problems with SSRIs (46:00) Short-Term vs. Long-Term Medication (53:50) TaperClinic --- Today's Sponsors: PreBorn — Would you consider a gift to save babies in a big way? Your gift will be used to save countless babies for years to come. To donate, dial #250 and say the keyword BABY or donate securely at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠preborn.com/allie⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Good Ranchers — Give a reason to gather. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠goodranchers.com⁠⁠⁠⁠⁠⁠⁠⁠⁠ to start gifting, and while you're there, treat yourself with your own subscription to America's best meat. And when you use the code ALLIE, you'll get $40 off your first order. EveryLife — Visit ⁠⁠⁠⁠⁠everylife.com⁠⁠⁠⁠⁠ and use promo code ALLIE10 to get 10% off your first order today!  Patriot Mobile — Switching to Patriot Mobile is easier than ever. Activate in minutes from your home or office. Keep your number, keep your phone, or upgrade. Go to ⁠⁠⁠patriotmobile.com/allie⁠⁠⁠ or call 972-PATRIOT, and use promo code ALLIE for a free month of service! Cozy Earth — Give the gift of everyday luxury this holiday season. Head to ⁠cozyearth.com⁠ and use the code RELATABLE for up to 40% off — just be sure to place your order by December 12 for guaranteed Christmas delivery. --- Episodes you might like:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ep 1189 | SSRIs Are Rewiring Babies' Brains — and Killing Their Moms | Guest: Dr. Adam Urato ⁠https://podcasts.apple.com/us/podcast/ep-1189-ssris-are-rewiring-babies-brains-and-killing/id1359249098?i=1000708507649⁠ Ep 821 | Why Antidepressants Don't Fix Depression | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-821-why-antidepressants-dont-fix-depression-guest/id1359249098?i=1000616890403⁠⁠ Ep 822 | The Big Money Behind Big Medicine | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-822-the-big-money-behind-big-medicine-guest-dr/id1359249098?i=1000617050991⁠⁠ Ep 1031 | Psychiatry Is Killing People | Guest: Dr. Roger McFillin ⁠⁠https://podcasts.apple.com/us/podcast/ep-1031-psychiatry-is-killing-people-guest-dr-roger/id1359249098?i=1000661830317⁠⁠ --- Buy Allie's book "You're Not Enough (and That's Okay): Escaping the Toxic Culture of Self-Love": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.alliebethstuckey.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Relatable merchandise: Use promo code ALLIE10 for a discount: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://shop.blazemedia.com/collections/allie-stuckey⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharma deal, Supreme Court on piracy, special election in Nashville, and a TSA record. Plus, the Message of the Day, on heaven and hell… Learn more about your ad choices. Visit megaphone.fm/adchoices